BioStock: Alligator Bioscience expands orphan designation to Europe

The regulatory milestones for Alligator Bioscience’s CD40 agonist mitazalimab keep rolling in. Before the summer break, Alligator was granted orphan drug designation for mitazalimab as a treatment for pancreatic cancer FDA. Now, the EMA has followed suit, giving mitazalimab orphan designation benefits for the European market.

Read the interview with Søren Bregenholt at biostock.se:

https://www.biostock.se/en/2023/08/alligator-bioscience-expands-orphan-designation-to-europe/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/